← back to search

Shugeng Gao

Mirati Therapeutics (United States) · CN
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Esophageal Cancer Research and Treatment, and Lung Cancer Treatments and Mutations.
h-index
39
citations
6,397
works
190
NIH funding
primary concept
Medicine
email

Recent publications

Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses
European Journal of Cancer 2026cited by 0position: contributordoi
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers
Med 2025cited by 9position: middledoi
Single-cell RNA sequencing and spatial transcriptomics of esophageal squamous cell carcinoma with lymph node metastases.
2025cited by 7position: contributordoi
Expert Consensus on Subxiphoid and Subcostal Arch Thoracoscopic Resection for the Treatment of Thymoma
Thoracic Cancer 2025cited by 3position: middledoi
Relationship between long-term outcomes and optimal time interval in patients with bilateral synchronous multiple primary lung cancers: a multi-institutional cohort study.
2025cited by 0position: contributordoi
Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
2024cited by 34position: contributordoi
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
New England Journal of Medicine 2023cited by 992position: middledoi
Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization.
2023cited by 46position: contributordoi
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial
BMC Medicine 2023cited by 43position: middledoi
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
2023cited by 37position: contributordoi
Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study.
2023cited by 22position: contributordoi
Utility of 18F-FDG uptake in predicting major pathological response to neoadjuvant immunotherapy in patients with resectable non‑small cell lung cancer
Translational Oncology 2023cited by 14position: contributordoi
Identification of lymphophilic subtype in resectable esophageal squamous cell carcinoma using genetic signatures from large-scale genomic repertoires
2023cited by 0position: contributordoi
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection
Molecular Cancer 2022cited by 85position: middledoi
Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma
eBioMedicine 2022cited by 67position: contributordoi
Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study
eBioMedicine 2022cited by 63position: contributordoi
Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
2022cited by 47position: contributordoi
RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer
eBioMedicine 2022cited by 35position: contributordoi
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade.
2022cited by 27position: contributordoi
International expert consensus on immunotherapy for early-stage non-small cell lung cancer
Translational Lung Cancer Research 2022cited by 25position: middledoi
Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.
2022cited by 10position: contributordoi
PSC subtyping based on TTF-1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies.
2022cited by 2position: contributordoi
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy
JAMA Oncology 2021cited by 229position: middledoi
Expert consensus on resection of chest wall tumors and chest wall reconstruction
Translational Lung Cancer Research 2021cited by 79position: middledoi
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Translational Lung Cancer Research 2021cited by 22position: middledoi
Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians.
2021cited by 15position: contributordoi
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Journal of Thoracic Oncology 2020cited by 408position: firstdoi
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
2020cited by 321position: contributordoi
Lymph node dissection and recurrent laryngeal nerve protection in minimally invasive esophagectomy
Annals of the New York Academy of Sciences 2020cited by 35position: middledoi
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
JAMA Oncology 2019cited by 495position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 17 papers (2021–2026)Qinfu Feng · Chinese Academy of Medical Sciences & Peking Union Medical College3 papers (2016–2021)Yousheng Mao · Chinese Academy of Medical Sciences & Peking Union Medical College3 papers (2016–2020)Zongmei Zhou · Huazhong Agricultural University3 papers (2016–2021)Jie He · First Affiliated Hospital of Jinan University3 papers (2017–2022)Jun Liang · Anhui Medical University3 papers (2016–2021) · 3 papers (2016–2021)Chun Chen · Sun Yat-sen University2 papers (2019–2020)Jie He · Northwestern University2 papers (2016–2020)Qi Xue · Tsinghua University2 papers (2016–2017)Lijun Tan · Sun Yat-sen University2 papers (2016–2017)Wei Guo · Chinese Academy of Medical Sciences Cancer Institute and Hospital2 papers (2023–2024)Xiaowei Chen · 2 papers (2024–2026) · 2 papers (2017–2021)Wei Deng · Guangzhou University of Chinese Medicine2 papers (2016–2017)Heather A. Wakelee · Stanford University1 papers (2023–2023)Olivier Bylicki · AlterSanté1 papers (2023–2023)Masahiro Tsuboi · National Cancer Center Hospital East1 papers (2023–2023)Jonathan Spicer · McGill University Health Centre1 papers (2023–2023)Ayman Samkari · Merck & Co., Inc., Rahway, NJ, USA (United States)1 papers (2023–2023)